Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral(TM) administration

Journal of the American Society of Nephrology

Volumn 8, Issue 4, 1997, Pages 647-652

  Gaspari, Flavio ^a   Anedda, Maria Franca ^a   Signorini, Orietta ^a   Remuzzi, Giuseppe ^a,b   Perico, Norberto ^a,b  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030717563     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v84647     Document Type: Article

References (21)

1. Kahan BD: Cyclosporine. N Engl J Med 321: 1725-1738, 1989
2. The Canadian Multicentre Transplant Study Group: A randomized clinical trial of cyclosporine in cadaveric renal transplantation: Analysis at three years. N Engl J Med 314: 1219-1225, 1986
3. Starzl TE, Klintmalm GBG, Porter KA, Iwatsuki S, Schroter GPJ: Liver transplantation with use of cyclosporin A and prednisone. N Engl J Med 305: 266-269, 1981
4. Macoviak JA, Oyer PE, Stinson EB, Jamieson SW, Baldwin JC, Shumway NE: Four-year experience with cyclosporine for heart and heart-lung transplantation. Transplant Proc 17[Suppl 2]: 97-101, 1985
5. Traeger J, Dubernard J, Pozza G: Influence of immunosuppressive therapy on the endocrine function of segmental pancreatic allografts. Transplant Proc 15: 1326-1329, 1983
6. Remuzzi G, Perico N: Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int 48[Suppl 52]: S70-S74, 1995
7. Myers BD: Cyclosporine nephrotoxicity. Kidney Int 30: 964-974, 1986
8. Klintmalm GBG, Säwe J, Ringdén O, Von Bahr C, Magnusson A: Cyclosporine plasma levels in renal transplant patients: Association with renal toxicity and allograft rejection. Transplantation 39: 132-137, 1985
9. Lindholm A, Kahan BD: Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 54: 205-218, 1993
10. Kahan BD, Shaw LM, Holt DW, Grevel J, Johnston A: Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem 36: 1510-1516, 1990
11. Kahan BD, Grevel J: Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 46: 631-644, 1988
12. Grevel J, Welsh MS, Kahan BD: Cyclosporine monitoring in renal transplantation: Area under the curve is superior to trough level monitoring. Ther Drug Monit 11: 246-248, 1989
13. Gaspari F, Ruggenenti P, Torre L, Bertocchi C, Remuzzi G, Perico N: Failure to predict cyclosporine area under the curve using a limited sampling strategy. Kidney Int 44: 436-439, 1993
14. Holt DW, Mueller EA, Kovarik JM, Van Bree JB, Kutz K: The pharmacokinetics of Sandimmune Neoral: A new oral formulation of cyclosporine. Transplant Proc 25: 2935-2939, 1994
15. Mueller EA, Kovarik JM: Van Bree JB, Lison AE, Kutz K: Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients: A concentration-controlled comparison with the commercial formulation. Transplantation 57: 1178-1182, 1994
16. Kahan BD, Dunn J, Fitts C, Van Buren D, Wombolt D, Pollak R, Carson R, Alexander JW, Choc M, Wong R: Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 59: 505-511, 1995
17. Perico N, Ruggenenti P, Gaspari F, Mosconi L, Benigni A, Amuchastegui CS, Gasparini F, Remuzzi G: Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 54: 56-60, 1992
18. The Canadian Neoral Study Group: A randomized, prospective multicentre pharmacoepidemiologic study of Neoral (cyclosporine microemulsion) in stable renal graft recipients [Abstract]. American Society of Transplant Physicians 15th Annual Meeting, Dallas, Texas. May 26-30, 1996, p 170
19. Amante A, Lindholm A, Welsh M, Kahan BD: Cyclosporine pharmacokinetic risk factors for acute rejection episodes in renal transplantation [Abstract]. American Society of Transplant Physicians 15th Annual Meeting, Dallas, Texas, May 26-30, 1996, p 224
20. Foradori AC, Martinez L, Elberg A, Vaccarezza A, Loveluck A, Pinto C: Preliminary pharmacokinetic evaluation of a new galenical formulation of oral cyclosporine A: Neoral TM. Transplant Proc 27: 1813-1814, 1995
21. Serafinowicz A, Gaciong Z, Baczkowska T, Rell K, Lao M: Limited sampling strategy to estimate exposure to CsA in renal allograft recipients (RARs) treated with Sandimmune-Neoral (NEO) [Abstract]. Second International Conference on New Trends in Clinical and Experimental Immunosuppression. Geneva, Switzerland, February 15-18, 1996, p 59